Autologous MSC-NTF cells
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 5 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
Showing 1 to 5 of 5 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04681118 (ClinicalTrials.gov) | March 24, 202120210324 | 18/12/202020201218 | Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Trea ... | Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Intermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (A ... | Amyotrophic Lateral Sclerosis | Biological: NurOwn (MSC-NTF cells) | Brainstorm-Cell Therapeutics | NULL | No longer available | 18 Years | 63 Years | All | United States | ||
| 2 | NCT03280056 (ClinicalTrials.gov) | August 28, 201720170828 | 29/8/201720170829 | Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients | A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Sa ... | Amyotrophic Lateral Sclerosis (ALS) | Biological: NurOwn® (MSC-NTF cells);Other: Placebo;Other: Bone Marrow aspiration | Brainstorm-Cell Therapeutics | California Institute for Regenerative Medicine (CIRM) | Completed | 18 Years | 60 Years | All | 263 | Phase 3 | United States |
| 3 | NCT02017912 (ClinicalTrials.gov) | May 201420140500 | 17/12/201320131217 | Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cellsi ... | A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Eff ... | Amyotrophic Lateral Sclerosis (ALS) | Biological: Autologous MSC-NTF cells;Biological: Placebo | Brainstorm-Cell Therapeutics | NULL | Completed | 18 Years | 75 Years | All | 48 | Phase 2 | United States |
| 4 | NCT01777646 (ClinicalTrials.gov) | December 201220121200 | 12/12/201220121212 | Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS) AutologousMesenchymal Bone Marrow Stromal CellsSecreting Neurotrophic Factors (MSC-NTF), in Patients ... | A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS). A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and The ... | Amyotrophic Lateral Sclerosis | Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF Biological: MSC_NTF cellstransplantation by multiple intramuscular injections at 24 separate sites, ... | Brainstorm-Cell Therapeutics | Hadassah Medical Organization | Completed | 20 Years | 75 Years | All | 14 | Phase 2 | Israel |
| 5 | NCT01051882 (ClinicalTrials.gov) | June 201120110600 | 17/1/201020100117 | Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. AutologousCultured Mesenchymal Bone Marrow Stromal CellsSecreting Neurotrophic Factors (MSC-NTF), in ... | A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients. A Phase I/II, Open Label Study to Evaluate Safety, Tolerability and Therapeutic Effects of Transplan ... | Amyotrophic Lateral Sclerosis | Biological: MSC-NTF cells transplantation (IM);Biological: MSC-NTF cells transplantation (IT) | Brainstorm-Cell Therapeutics | Hadassah Medical Organization | Completed | 20 Years | 75 Years | All | 12 | Phase 1/Phase 2 | Israel |